Comparative Pharmacology
Head-to-head clinical analysis: GEODON versus NUPLAZID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEODON versus NUPLAZID.
GEODON vs NUPLAZID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ziprasidone is an atypical antipsychotic with high affinity for dopamine D2 and serotonin 5-HT2A receptors; it also antagonizes 5-HT2C, 5-HT1D, alpha1-adrenergic, and histamine H1 receptors, and moderately inhibits serotonin and norepinephrine reuptake.
Selective serotonin 5-HT2A receptor inverse agonist and antagonist; also has moderate affinity for 5-HT2C and 5-HT1A receptors.
20 mg orally twice daily with food; may titrate to 40-80 mg orally twice daily; maximum 80 mg orally twice daily. For acute treatment, IM 10-20 mg as needed up to 40 mg/day.
34 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for oral ziprasidone; after intramuscular administration, half-life is about 2-5 hours. This short half-life may require twice-daily dosing for oral therapy.
Terminal elimination half-life is approximately 50 hours (range 40-70 hours), allowing once-daily dosing.
Primarily hepatic metabolism via aldehyde oxidase and CYP3A4. Approximately 20% excreted renally as unchanged drug, with the remainder as metabolites (mostly fecal).
Fecal (approximately 60%) as unchanged drug and metabolites; renal (approximately 13%) as unchanged drug and metabolites.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic